Everyday Health on MSN

How to Deal With Musculoskeletal Pain in MS (And Why It Happens)

Learn how to manage musculoskeletal pain in multiple sclerosis. Discover causes, symptoms, diagnosis, and effective treatment ...

All you need to know about: Amyotrophic lateral sclerosis

Learn about Amyotrophic Lateral Sclerosis (ALS), its symptoms, risk factors, diagnosis, and current research advancements.

Free drug coverage ended, Manitoban battling degenerative disease asks province to step up

A man who has gradually lost his ability to move most of his muscles said the treatment he’s relying on to slow — and even ...

Novartis receives FDA approval for Itvisma(R), the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

The ultimate caregiver’s handbook for Parkinson’s

Parkinson’s Disease Causes, Symptoms, and Treatment Parkinson’s disease (PD) is one of the fastest-growing neurological ...

Confident, Kind, Athletic: The Golden Retriever

With their bright temperament and trademark Golden Retriever energy, these dogs thrive on engagement, exercise and close ...

Mohave County Sheriff's Office K9 to undergo amputation surgery

The Mohave County Sheriff's K9, Brutus, will undergo leg amputation due to nerve damage from a 2022 crash. PHOENIX — The ...
TAG24

Ataxia in cats: Explaining the medical condition, its causes, and treatment options

Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...

US FDA approves Novartis' gene therapy for rare muscle disorder

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.

Novartis Drug for Spinal Muscular Atrophy Gets FDA Approval

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

FDA approves Novartis' gene therapy for rare muscle disorder

U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said ...
The Malaysian Reserve

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase ...